BMS and Avidity Biosciences Signs a Collaboration Agreement Worth $2.3B to Advance Cardiovascular Treatments
Shots:
- Avidity Biosciences and BMS have entered a global collaboration to advance cardiovascular treatments using Antibody Oligonucleotide Conjugates (AOCs)
- The deal includes potential payments of up to $2.3B, with BMS making a $60M up front cash payment & investing $40M in Avidity's stock. Additional payments include up to $1.35B in research & development milestones, up to $825M in commercial milestones, and low double-digits tiered royalties on net sales
- The collaboration reinforces Avidity's commitment to cardiology, leveraging its AOC platform to address previously untreatable diseases with RNA therapeutics. The partnership expands on prior research with MyoKardia & highlights the broad potential of AOC technology
Ref: PR Newswire | Image: Avidity Biosciences
Related News:- Avidity Biosciences Reports the US FDA's Clinical Hold on P-I/II (MARINA) Trial of AOC 1001 for Myotonic Dystrophy Type 1
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
